Larimar Therapeutics, Inc. (LRMR)Healthcare | Biotechnology | Bala Cynwyd, United States | NasdaqGM
4.77 USD
-0.05
(-0.936%) ⇩
(April 21, 2026, 1:42 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:48 p.m. EDT
Institutional upgrading and analyst target hikes support a bullish bias, evidenced by the massive OI buildup at higher strike calls and a lack of defensive put activity. However, the long-term bullish thesis remains fragile due to negative fundamentals and recent price corrections, making this a speculative trade rather than a certainty. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.236284 |
| MSTL | 0.237329 |
| AutoETS | 0.237995 |
| AutoARIMA | 0.245818 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 50% |
| H-stat | 4.18 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.135 |
| Excess Kurtosis | -1.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.208 |
| Market Cap | 495,002,176 |
| Forward P/E | -2.68 |
| Beta | 1.02 |
| Website | https://www.larimartx.com |
As of April 18, 2026, 11:48 p.m. EDT: Calls show a constructive imbalance with OI heavily skewed out-of-the-money (OTM), particularly in the $7.50–$26.00 range, while Put OI is concentrated deep out-of-the-money at the $2.50 strike, indicating low urgency for downside protection. The recent 1.2k volume surge at the $2.50 put strike vs. low 1.2k total volume elsewhere suggests some hedging activity, but the dominance of Call flow (especially the +160% OI jump at the $12.50 strike) signals that option flow is primarily bullish. Implied Volatility is elevated, reflecting anticipated pre-FDA filing volatility, but the net positioning favors an upside move.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0210085 |
| Address1 | Three Bala Plaza East |
| Address2 | Suite 506 |
| All Time High | 664.32 |
| All Time Low | 1.53 |
| Ask | 5.97 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 1,301,500 |
| Average Daily Volume3 Month | 4,288,472 |
| Average Volume | 4,288,472 |
| Average Volume10Days | 1,301,500 |
| Beta | 1.023 |
| Bid | 3.41 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 0.94 |
| City | Bala Cynwyd |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.765 |
| Current Ratio | 2.192 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.835 |
| Day Low | 4.6312 |
| Debt To Equity | 5.208 |
| Display Name | Larimar Therapeutics |
| Dividend Date | 1,590,710,400 |
| Earnings Timestamp | 1,773,923,400 |
| Earnings Timestamp End | 1,777,465,800 |
| Earnings Timestamp Start | 1,777,465,800 |
| Ebitda | -172,147,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.131 |
| Enterprise Value | 366,891,936 |
| Eps Current Year | -2.18704 |
| Eps Forward | -1.77954 |
| Eps Trailing Twelve Months | -2.27 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.5115 |
| Fifty Day Average Change | 0.25349998 |
| Fifty Day Average Change Percent | 0.056189734 |
| Fifty Two Week Change Percent | 102.100845 |
| Fifty Two Week High | 6.42 |
| Fifty Two Week High Change | -1.6550002 |
| Fifty Two Week High Change Percent | -0.25778818 |
| Fifty Two Week Low | 1.73 |
| Fifty Two Week Low Change | 3.0349998 |
| Fifty Two Week Low Change Percent | 1.7543352 |
| Fifty Two Week Range | 1.73 - 6.42 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,403,184,600,000 |
| Float Shares | 54,986,277 |
| Forward Eps | -1.77954 |
| Forward P E | -2.6776583 |
| Free Cashflow | -53,473,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 71 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00881 |
| Held Percent Institutions | 0.75238 |
| Implied Shares Outstanding | 103,882,937 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania. |
| Long Name | Larimar Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 495,002,176 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_572350487 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -165,672,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 500,196,341 |
| Number Of Analyst Opinions | 10 |
| Open | 4.82 |
| Operating Cashflow | -113,201,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 844 511 9056 |
| Previous Close | 4.81 |
| Price Eps Current Year | -2.1787438 |
| Price Hint | 4 |
| Price To Book | 5.069149 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.124 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.045000076 |
| Regular Market Change Percent | -0.93555254 |
| Regular Market Day High | 4.835 |
| Regular Market Day Low | 4.6312 |
| Regular Market Day Range | 4.6312 - 4.835 |
| Regular Market Open | 4.82 |
| Regular Market Previous Close | 4.81 |
| Regular Market Price | 4.765 |
| Regular Market Time | 1,776,793,340 |
| Regular Market Volume | 459,214 |
| Return On Assets | -0.62306 |
| Return On Equity | -1.32593 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 103,882,937 |
| Shares Percent Shares Out | 0.0735 |
| Shares Short | 7,639,333 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 7,692,689 |
| Short Name | Larimar Therapeutics, Inc. |
| Short Percent Of Float | 0.1015 |
| Short Ratio | 3.33 |
| Source Interval | 15 |
| State | PA |
| Symbol | LRMR |
| Target High Price | 26.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 16.7 |
| Target Median Price | 16.0 |
| Total Cash | 136,852,000 |
| Total Cash Per Share | 1.317 |
| Total Debt | 4,067,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.27 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.95095 |
| Two Hundred Day Average Change | 0.81404996 |
| Two Hundred Day Average Change Percent | 0.20603904 |
| Type Disp | Equity |
| Volume | 459,214 |
| Website | https://www.larimartx.com |
| Zip | 19,004 |